NEW YORK (GenomeWeb) – Thermo Fisher Scientific reported before the opening of the market on Thursday that its second quarter revenues increased 6 percent, thanks in part to large increases in laboratory products and services revenues and life sciences solutions revenues.

Separately today, Thermo Fisher said that it has signed a deal with Health BioMed to support that company's efforts to develop molecular diagnostic kits for infectious disease and pharmacogenomics screening for the Chinese market.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.